Analysis of Unani coded formulation on the hormonal parameters of patients with polycystic ovarian syndrome
Abstract
The effect of Unani coded polyherbal formulations (Picolin) containing: 1) Cinnamomum verum (Bark), 2) Glycyrrhiza glabra (Root), 3) Linum usitatissimum (Seed) and 4) Vitex agnus castus (Seed) on the hormonal levels of polycystic ovarian syndrome (PCOS) patients (n=73) was determined. A randomized controlled multi-center trial was conducted on three groups that received either: 1) Capsule Picolin (n=25, 500 mg, two capsules thrice a day) and 2) Hydroalcoholic extract, tablet Picolin-E (n=23, 250 mg thrice a day) or 3) Metformin (n=25, 500 mg, twice a day) that continued for 12 weeks. The effect of capsule Picolin before and after treatment on serum insulin (14.8±1.8 vs 10.7±1.7μIU/mL) and prolactin (17.7±0.9 vs 8.5±1.1ng/mL) levels were significant. Likewise, the tablet Picolin-E also demonstrated significant effect on serum insulin (16.7±1.7 vs 9.3±0.1μIU/mL) and prolactin (18.5±1 vs 10±1.5ng/mL) levels. On the contrary in metformin treated group these parameters, serum insulin (17.4±1.6 vs 16.4±1.4μIU/mL) and prolactin (21.7±2.8 vs 21±2.8ng/mL) were non-significant. The improvement in the menstrual flow in the PCOS patients after treatment with either capsule Picolin, tablet Picolin-E or metformin were improved by 84%, 61% and 54%, respectively. Unani formulation were comparatively more effective than metformin. The treatment effectiveness was capsule Picolin> tablet Picolin-E>metformin.
How strong is the evidence?
Evidence Hub reads this as a randomized trial, done in people. Its evidence level is 2 of 5 (High · randomized trial). Randomized trials of a reasonable size are the strongest single-study design. Reported size: 73 participants or records.
Read the paper
Related studies
- Increased expression of circulating miRNA-93 in women with polycystic ovary syndrome may represent a novel, non-invasive biomarker for diagnosis
- Identification of key genes associated with polycystic ovary syndrome (PCOS) and ovarian cancer using an integrated bioinformatics analysis
- Identification of key pathways and genes in polycystic ovary syndrome via integrated bioinformatics analysis and prediction of small therapeutic molecules
- Regulation of Androgen Receptor Expression Alters AMPK Phosphorylation in the Endometrium: In Vivo and In Vitro Studies in Women with Polycystic Ovary Syndrome
- Effect of oral administration of low-dose follicle stimulating hormone on hyperandrogenized mice as a model of polycystic ovary syndrome
- Systems pharmacology to investigate the interaction of berberine and other drugs in treating polycystic ovary syndrome
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.